Payment reform's impact on socioeconomic disparities may not matter if the growth in healthcare expenditures in the United States means the government or payers can’t afford to pay for the medicines, said Andrew L. Pecora, MD, FACP, CPE, chief innovation officer professor and vice president of cancer services at the John Theurer Cancer Center.
Andrew L. Pecora, MD, FACP, CPE: It’s a complex question because socioeconomic impact, it’s not a unidirectional issue. So, on the one hand, people who are less fortunate socioeconomically, they have a number of challenges that go beyond the disease they have. Can they get to the doctor’s office because they don’t own a car? Can they miss work because they need to work to pay to live? Do they live in an environment that’s a healthy environment where they’re getting good fresh food? All of those things impact. That’s one issue.
Compliance to prescribed therapy is another. It’s very hard sometimes, particularly with serious illness, when you have a family to deal with, you have a job, you don’t feel good, and then you have medications that are very expensive, and you have to take them in a frequency that is a challenge to you. That if you’re in a lower socioeconomic group, that may be a problem.
So, when you think about payment reform, what is it trying to do? I think it’s on a different level than that issue. I think the issue is is that it’s a zero sum game. Despite the fact we’re the most prosperous nation on the planet Earth, we can’t afford to sustain the growth in healthcare expenditures. Everyone agrees with that, and the problem we have right now is that the pace of acceleration is increasing in regard to discovery, and discovery, every new discovery drives more expense. So you have more discovery, more expense, people living longer because of these wonderful new drugs but costing more, and we can’t afford that.
The point we’re coming to, which would be a crisis point, is at some point we’d have to ration care. And then, regardless of your socioeconomic status—you could be rich, you could be poor—if the government or payers can’t afford to pay for the medicines, well, then you’re not going to get them. And so I think it’s a 2-tiered issue on the personal level, on the human level. There are challenges that payment reform might in part disproportionately on someone who doesn’t have the means of someone who does, but on the bigger level, if that patient, regardless of their means needs a certain medication and we can’t afford to give it to them, that’s a whole other problem.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More